Evidence map›Paper›PMID 42798817›Full record

ReviewGastroenterology report2026

Navigating TIPS in the era of ageing and metabolic comorbidity: a contemporary narrative review of risk, resilience, and outcomes.

Davide Roccarina, Dario Saltini, Chiara Mangini, Antonio Piscopo, Alessio Mastro, Alessandra Barbera, Andrea Salomè Velasco Mayorga, Alessandra Avossa, Lucia Ragozzino, Margherita Falcini and 8 more

Abstract readReview
In one paragraph

Review in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Davide RoccarinaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Dario SaltiniSevere Liver Diseases Departmental Unit (M.E.C.), AOU Policlinico of Modena, CHIMOMO Department University of Modena and Reggio Emilia, Modena, Italy.
Chiara ManginiDepartment of Medicine (DIMED), University of Padova, Padova, Italy.
Antonio PiscopoSevere Liver Diseases Departmental Unit (M.E.C.), AOU Policlinico of Modena, CHIMOMO Department University of Modena and Reggio Emilia, Modena, Italy.
Alessio MastroDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Alessandra BarberaDepartment of Medicine (DIMED), University of Padova, Padova, Italy.
Andrea Salomè Velasco MayorgaSevere Liver Diseases Departmental Unit (M.E.C.), AOU Policlinico of Modena, CHIMOMO Department University of Modena and Reggio Emilia, Modena, Italy.
Alessandra AvossaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Lucia RagozzinoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Margherita FalciniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Martina RosiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Alfredo VozzaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Gianmarco FalconeDepartment of Radiology, Interventional Radiology Unit, Careggi University Hospital, Florence, Italy.
Fabrizio FanelliDepartment of Radiology, Interventional Radiology Unit, Careggi University Hospital, Florence, Italy.
Fabio MarraDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Sara MontagneseDepartment of Medicine (DIMED), University of Padova, Padova, Italy.
Filippo SchepisSevere Liver Diseases Departmental Unit (M.E.C.), AOU Policlinico of Modena, CHIMOMO Department University of Modena and Reggio Emilia, Modena, Italy.
Francesco VizzuttiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID https://orcid.org/0000-0002-3014-8968

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ageing of the cirrhotic population, together with the epidemiological shift toward metabolic dysfunction-associated steatohepatitis, is redefining the profile of patients referred for transjugular intrahepatic portosystemic shunt (TIPS). Although TIPS remains a cornerstone in the management of complications of portal hypertension, its abrupt hemodynamic and metabolic effects challenge the physiological reserve of multiple organ systems. Age-related cardiovascular remodeling, cirrhotic cardiomyopathy, impaired renal function and autoregulation, and reduced neurocognitive reserve interact with the hyperdynamic circulatory state of cirrhosis increasing the susceptibility to heart failure, acute kidney injury (AKI), and hepatic encephalopathy following TIPS. This vulnerability is further amplified by metabolic comorbidities, obesity, sarcopenia, frailty, and age-related alterations of the gut microbiota and gut-liver axis, which collectively promote systemic inflammation, immune dysregulation, endothelial dysfunction, and reduced metabolic adaptability. Rather than independently, these factors shape an interconnected heart-liver-kidney-brain network in which dysfunction in one domain may rapidly propagate to others. This review summarizes how ageing influences the cardiovascular, renal, neurological, and metabolic response to TIPS, critically appraises current strategies for pre-procedural risk assessment, and discusses approaches to improve patient selection and peri-procedural management. Because chronological age alone inadequately reflects procedural risk and clinical outcomes, TIPS evaluation should incorporate a structured assessment of biological ageing, including cardiovascular and renal reserve, neurocognitive vulnerability, sarcopenia, frailty, body-composition phenotype, and metabolic burden. Integrating these domains into pre-procedural assessment may improve patient selection, inform shunt sizing, and ultimately optimize outcomes in this rapidly evolving patient population.

Indexed as

cirrhosishepatic encephalopathyolder adultsportal hypertension, under-dilated endoprosthesis

Identifiers

PMID42798817
PMCPMC13613062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.